Substituted azoles

US6579874B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Laszlo Revesz · Therwil, CH
• Achim Schlapbach · Bad Kötzting, DE

Key dates

• Filing date: Oct 12, 2001
• Grant date: Jun 17, 2003
• Expiry date: Oct 12, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula I wherein the symbols have meaning as defined herein, are p38 MAP kinase inhibitors, and are useful pharmaceutically for treating TNF&agr; and IL-1 mediated diseases, such as rheumatoid arthritis, and diseases of bone metabolism, e.g. osteoporosis.